Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Lie, S OAbrahamsson, J
Clausen, N
Forestier, E
Hasle, H
Hovi, L
Jonmundsson, G
Mellander, L
Siimes, M A
Yssing, M
Zeller, B
Gustafsson, G
Issue Date
2005-12-01
Metadata
Show full item recordCitation
Leukemia 2005, 19(12):2090-100Abstract
In all, 447 children with acute myeloid leukaemia (AML) have been treated on three consecutive NOPHO studies from July 1984 to December 2001. NOPHO-AML 84 was of moderate intensity with an induction of three courses of cytarabine, 6-thioguanine and doxorubicin followed by four consolidation courses with high-dose cytarabine. The 5-year event-free survival (EFS), disease free survival (DFS) and overall survival (OS) were 29, 37 and 38%. NOPHO-AML 88 was of high intensity with the addition of etoposide and mitoxantrone in selected courses during induction and consolidation. The interval between the induction courses should be as short as possible, that is, time intensity was introduced. The 5-year EFS, DFS and OS were 41, 48 and 46%. In NOPHO-AML 93, the treatment was stratified according to response to first induction course. The protocol utilised the same induction blocks as NOPHO-AML 88, but after the first block, children with a hypoplastic, nonleukaemic bone marrow were allowed to recover before the second block. Consolidation was identical with NOPHO-AML 88. The 5-year EFS, DFS and OS in NOPHO-AML 93 were 48, 52 and 65%. The new NOPHO-AML protocol has been based on experiences from previous protocols with stratification of patients with regard to in vivo response and specific cytogenetic aberrations.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Link fieldAdditional Links
http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=18943404&site=ehost-liveae974a485f413a2113503eed53cd6c53
10.1038/sj.leu.2403962
Scopus Count
Collections
Related articles
- Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
- Authors: Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, Weinstein HJ, Pediatric Oncology Group.
- Issue date: 2005 Dec
- Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.
- Authors: Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS, Harrison CJ
- Issue date: 2005 Dec
- Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
- Authors: Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M, Tokyo Children's Cancer Study Group.
- Issue date: 2007 Aug
- Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials.
- Authors: Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, Jonmundsson G, Mellander L, Gustafsson G
- Issue date: 2003 Jul
- Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia.
- Authors: Dluzniewska A, Balwierz W, Armata J, Balcerska A, Chybicka A, Kowalczyk J, Matysiak M, Ochocka M, Radwanska U, Rokicka-Milewska R, Sonta-Jakimczyk D, Wachowiak J, Wysocki M
- Issue date: 2005 Dec